These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19020261)

  • 21. Special issue: nephrogenic systemic fibrosis.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
    [No Abstract]   [Full Text] [Related]  

  • 22. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis.
    Marckmann P; Nielsen AH; Sloth JJ
    Nephrol Dial Transplant; 2008 Oct; 23(10):3280-2. PubMed ID: 18436563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of a screening instrument for nephrogenic systemic fibrosis.
    Lima XT; Alora-Palli MB; Kimball AB; Kay J
    Arthritis Care Res (Hoboken); 2013 Apr; 65(4):637-42. PubMed ID: 23097320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
    Wang SC
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
    [No Abstract]   [Full Text] [Related]  

  • 28. MRI safety: nephrogenic systemic fibrosis and other risks.
    Gauden AJ; Phal PM; Drummond KJ
    J Clin Neurosci; 2010 Sep; 17(9):1097-104. PubMed ID: 20542435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renovascular imaging in the NSF Era.
    Roditi G; Maki JH; Oliveira G; Michaely HJ
    J Magn Reson Imaging; 2009 Dec; 30(6):1323-34. PubMed ID: 19937926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of NSF: New evidence challenging the prevailing theory.
    Newton BB; Jimenez SA
    J Magn Reson Imaging; 2009 Dec; 30(6):1277-83. PubMed ID: 19937925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era.
    Thomson LK; Thomson PC; Kingsmore DB; Blessing K; Daly CD; Cowper SE; Roditi GH
    J Magn Reson Imaging; 2015 May; 41(5):1268-71. PubMed ID: 24903851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy.
    Foss C; Smith JK; Ortiz L; Hanevold C; Davis L
    Pediatr Dermatol; 2009; 26(5):579-82. PubMed ID: 19840315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
    J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1357-63. PubMed ID: 19937935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk.
    Nicholas BA; Vricella GJ; Smith M; Passalacqua M; Gulani V; Ponsky LE
    Can J Urol; 2012 Feb; 19(1):6074-80. PubMed ID: 22316507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Findings of osseous sclerotic bodies: a unique sequence of cutaneous bone formation in nephrogenic systemic fibrosis.
    Kartono F; Basile A; Roshdieh B; Schwimer C; Shitabata PK
    J Cutan Pathol; 2011 Mar; 38(3):286-9. PubMed ID: 20726931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrogenic systemic fibrosis: clinical spectrum of disease.
    Mayr M; Burkhalter F; Bongartz G
    J Magn Reson Imaging; 2009 Dec; 30(6):1289-97. PubMed ID: 19937929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.